Filipendula ulmaria In 1897, Felix Hoffmann created a synthetically altered version of salicin, derived from the species, which caused less digestive upset than pure salicylic acid. The new drug, formally acetylsalicylic acid, was named aspirin by Hoffmann's employer Bayer AG after the old botanical name for meadowsweet, "Spiraea ulmaria". This gave rise to the class of drugs known as non-steroidal anti-inflammatory drugs (NSAIDs). A natural black dye can be obtained from the roots by using a copper mordant. A tea made from "Filipendula ulmaria" flowers or leaves has been used in traditional Austrian herbal medicine for the treatment of rheumatism, gout, infections,
Clodronic acid Clodronic acid is approved for use in horses under the trade name Osphos, for treatment of bone resorptive processes of navicular syndrome. It is given by intramuscular injection at one point in time, with the total dose divided into 2-3 sites on the horse. Clinical effects (e.g. improvement of lameness) after a single treatment can be seen up to 6 months post-treatment. Clodronic acid has been shown to have several adverse effects. These include: Clodronic acid Clodronic acid (INN) or clodronate disodium (USAN) is a first generation (non-nitrogenous) bisphosphonate. It is an anti-osteoporotic drug approved for the prevention and treatment